We investigated the associations of hemoglobin A 1c (HbA 1c ), glycated albumin (GA), GA/HbA 1c ratio, and 1,5-anhydroglucitol (1,5-AG) with the development of Alzheimer's disease (AD).
growing body of evidence indicates that diabetes mellitus is an important risk factor for the development of Alzheimer's disease (AD), the most common type of dementia (1, 2) . We previously reported that subjects with higher 2-hour postload glucose in an oral glucose tolerance test, but not those with higher fasting plasma glucose, had a significantly higher risk of developing AD (3) as well as formation of neuritic plaques (4) and hippocampal atrophy (5) , which are neuropathological and morphological characteristics of AD. Some crosssectional studies using continuous glucose monitoring (CGM) have also shown that postprandial hyperglycemia or acute glucose fluctuations were significantly related to cognitive impairment (6, 7) . These findings suggest that postprandial glucose excursion is a contributing factor to the development of AD. However, oral glucose tolerance test and CGM are costly and inconvenient in clinical settings, and thus it would be clinically valuable to identify a simple and practical measure that reflects postprandial hyperglycemia or glucose fluctuations and is associated with future risk of AD.
Hemoglobin A 1c (HbA 1c ) is a marker of chronic hyperglycemia and is widely used as the standard measure of glycemic control. Some prospective studies have focused on the association between HbA 1c levels and the risk of dementia, including AD (8) (9) (10) (11) , but the findings were inconsistent. In contrast, glycated albumin (GA) and 1,5-anhydroglucitol (1,5-AG), which are alternative measures of hyperglycemia, have attracted clinical attention as markers of postprandial glucose excursion (12) (13) (14) . In addition, the GA/HbA 1c ratio has recently been proposed as a measure for estimating acute increase in plasma glucose levels, because glycation of albumin occurs more rapidly than that of hemoglobin (12, 14) . It is apparent that GA levels increase rapidly in response to a steep rise of plasma glucose levels, whereas HbA 1c levels are elevated gradually, because of the much shorter half-life of albumin compared with hemoglobin (14) . A clinical study has shown that the GA/HbA 1c ratio was significantly associated with postprandial plasma glucose, but not with fasting plasma glucose (15) . Another clinical study demonstrated that the GA/HbA 1c ratio had a correlation with glucose excursion evaluated by CGM (16) . These findings raise the possibility that the GA/HbA 1c ratio is a good indicator of postprandial glucose fluctuation. Moreover, a recent cross-sectional study reported that a higher GA/ HbA 1c ratio was significantly associated with cognitive impairment (17) . Thus, it would be reasonable to suppose that there is a link between these alternative measures of hyperglycemia and incident AD. However, prospective cohort studies addressing this issue are quite limited (18) .
The purpose of the present work was to examine the associations of HbA 1c , GA, the GA/HbA 1c ratio, and 1,5-AG levels with the development of AD in a prospective study of an elderly Japanese population.
Methods

Study population
A population-based prospective study of cerebro-cardiovascular diseases and their risk factors has been underway since 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area on Japan's Kyushu Island (3, 19) . In addition, comprehensive surveys of cognitive impairment in the elderly adults of the town have been carried out every 6 or 7 years since 1985 (20) . In 2007 and 2008, among a total of 1785 residents aged $65 years based on the town registry, 1581 (88.6%) took part in a screening survey for the current study. After exclusion of 3 participants who did not consent to participate in the study, 165 with dementia at baseline, and 226 without measurement of HbA 1c , GA, or 1,5-AG, the remaining 1187 subjects (535 men and 652 women) were enrolled in the current study.
Follow-up survey
The subjects were followed up prospectively from the date of their comprehensive assessment to November 2012. Detailed information about the follow-up survey on dementia has been described elsewhere (3, 19) . Briefly, a daily monitoring system was established with the study team and local physicians or members of the town's Health and Welfare Office to obtain information about new neurologic events, including stroke and dementia. The development of stroke and dementia was also checked by the annual health examinations. For subjects who did not undergo a regular examination or who had moved out of town, information on their health status was collected yearly through mail or telephone. In addition, a follow-up screening survey of cognitive function, including neuropsychological tests, the Hasegawa Dementia Scale-Revised (21) and the MiniMental State Examination (22) , was conducted in 2012. When new neurologic symptoms, including cognitive impairment, were suspected, the subject was carefully evaluated by a psychiatrist of the study team, who conducted a comprehensive investigation, including interviews of the family or attending physician, physical and neurologic examinations, and a review of the clinical records. In addition, when a subject died, an autopsy was performed at the Departments of Pathology of Kyushu University. During the follow-up, none of the subjects was lost to follow-up, and 92 subjects died, 54 of whom (58.7%) underwent brain examination at autopsy.
Diagnosis of AD
The guidelines of the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, were used to define the diagnosis of dementia (23) . As described previously (3, 19) , the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association were used to determine subjects with AD (24) . Clinical information, including neuroimaging, was used to diagnose possible and probable AD. Definite AD was also determined on the basis of clinical and neuropathological information in dementia subjects who underwent autopsy. The diagnostic procedure for autopsy cases has been reported previously (25) . Each case of dementia was adjudicated by expert stroke physicians and psychiatrists.
During the average 4.8-year follow-up period, 116 subjects developed AD. Of these, 106 subjects (91.4%) underwent brain imaging (n = 105) and/or autopsy (n = 4) to evaluate the brain morphological changes.
Measurements of HbA 1c , GA, and 1,5-AG The methods used for the baseline examination have been described previously (26) . HbA 1c levels were measured by latex aggregation immunoassay (Determiner HbA1C; Kyowa Medex, Tokyo, Japan). The values for HbA 1c were estimated as a National Glycohemoglobin Standardization Program equivalent value calculated with the following formula: HbA 1c (%) = 1.02 3 HbA 1c (Japan Diabetes Society) (%) + 0.25% (27) . Serum specimens were collected and stored at 280°C for 5 years until they were used for measurement of GA and 1,5-AG in 2012. Serum GA levels were determined by an enzymatic method using an albumin-specific proteinase, ketoamine oxidase, and an albumin assay reagent (Lucica GA-L; Asahi Kasei Pharma, Tokyo, Japan). Serum 1,5-AG concentrations were measured enzymatically (Lana 1,5AG Auto Liquid; Nippon Kayaku, Tokyo, Japan). Previous studies have reported the stability of GA and 1,5-AG measurements in frozen stored serum samples (28, 29) .
Other risk factors
Details about other risk factor measurements are described in Supplemental Methods.
Statistical analysis
The SAS software package version 9.3 (SAS Institute, Cary, NC) was used to perform all statistical analyses. Each of HbA 1c , GA, the GA/HbA 1c ratio, and 1,5-AG levels were divided into quartiles. The differences in the mean values or frequencies of potential risk factors for dementia between the lowest and the highest quartiles of each glycemic measure were assessed using the linear regression model or x 2 test, respectively. The incidence of AD was calculated by a person-year method and was adjusted for the age and sex distribution of the overall study population using the direct method; the differences and trends among levels of glycemic measures were tested using Cox's proportional hazards model. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for the development of AD were also estimated using Cox's proportional hazards model. Because serum 1,5-AG levels are decreased in the presence of hyperglycemia, the highest quartile was used as the reference category for 1,5-AG, whereas the lowest quartile was defined as the reference group for other glycemic measures. The heterogeneity in the association according to glucose tolerance status, sex, age, and levels of dietary factors was assessed by adding an interaction term to the relevant Cox model. A value of P , 0.05 was considered statistically significant in all analyses.
Ethical considerations
This study was conducted with the approval of the Kyushu University Institutional Review Board for Clinical Research, and written informed consent was obtained from all subjects.
Results
The baseline clinical characteristics of subjects were compared between the lowest and highest quartile of each glycemic measure in Table 1 . Subjects with the highest quartile of HbA 1c levels had higher serum total cholesterol and alanine aminotransferase (ALT) values and frequencies of hypertension, obesity, and history of stroke, and a significantly lower frequency of alcohol intake than those with the lowest quartile. For GA, the mean value of age and frequencies of history of stroke, anemia, and renal failure were higher in subjects with the highest quartile than in those with the lowest quartile, and the former had lower total cholesterol values and frequencies of alcohol intake and smoking habits. Similar distributions were observed in subjects with the highest quartile of GA/HbA 1c ratio, except for serum ALT values and the frequencies of women and obesity, which were lower in those with the highest We estimated the age-and sex-adjusted incidence of AD according to the quartiles of each glycemic measure (Fig. 1) . The incidence of AD increased significantly with higher GA/HbA 1c ratio levels (P for trend , 0.01) and appreciably, but not significantly, with elevating GA (P for trend = 0.06), but no such associations were found for HbA 1c and 1,5-AG. As shown in Table 2 , the significant positive association of the GA/HbA 1c ratio with the risk of AD remained robust even after adjustment for potential confounding factors: namely, age, sex, hypertension, total cholesterol, body mass index category (underweight, normal, and obesity), history of stroke, low education, smoking habits, alcohol intake, and physical activity (P for trend = 0.01), and the multivariable-adjusted HR for AD was significantly higher in subjects in the third (HR: 2.11; 95% CI: 1.16 to 3.82; P = 0.01) and fourth (HR: 2.01; 95% CI: 1.09 to 3.68; P = 0.02) quartile of the GA/HbA 1c ratio compared with those in the first quartile. These associations were not substantially altered even after additional adjustment for diabetes-related factors, including antidiabetic medication and duration of diabetes.
We next performed a subgroup analysis for AD according to glucose tolerance status (Fig. 2) . In this analysis, each glycemic measure was divided into high and low levels using its median value because of the limited sample size. In subjects with normal glucose tolerance, subjects with high GA/HbA 1c ratio levels had a significantly greater risk of AD than those with low GA/HbA 1c (multivariableadjusted HR: 1.82; 95% CI: 1.05 to 3.16; P = 0.03). A similar tendency was seen in subjects with glucose intolerance (multivariable-adjusted HR: 1.73; 95% CI: 0.96 to 3.13; P = 0.07). Meanwhile, no such associations were observed for HbA 1c , GA, and 1,5-AG, regardless of glucose tolerance status (all P . 0.1). There were no clear differences in the influence of each glycemic measure on the risk of AD between subjects with and those without glucose intolerance (all P for heterogeneity . 0.1). In addition, there was no evidence of heterogeneity between the sexes, age groups (,75 and $75 years), and levels of dietary factors (intakes of total energy, carbohydrate, protein, and fat) in the associations of each glycemic measure with the risk of AD (all P for heterogeneity . 0.1) (Supplemental Fig. 1A and 1B) .
Because HbA 1c , GA, the GA/HbA 1c ratio, and 1,5-AG levels may be affected by chronic conditions, we also performed sensitivity analyses with additional adjustment for serum ALT after excluding subjects with anemia, renal failure, or underweight. As shown in Supplemental Table 2, the findings were not substantially altered.
Discussion
Using data from a prospective study of an elderly Japanese population, we demonstrated that elevated levels of the GA/HbA 1c ratio, but not HbA 1c , GA, or 1,5-AG, were closely associated with the risk of developing AD. Intriguingly, high GA/HbA 1c ratio levels increased the risk of AD both in subjects with and those without glucose intolerance. The GA/HbA 1c ratio can be measured easily in a single blood test without fasting or glucose load, and thus, the GA/HbA 1c ratio would be a useful and practical tool to identify individuals at increased risk of AD.
This prospective longitudinal study demonstrates a significant association between elevated GA/HbA 1c ratio levels and the development of AD in a community-based population. To date, there has been only one crosssectional study addressing the association between the GA/HbA 1c ratio and cognitive impairment in a Chinese population, which revealed that the GA/HbA 1c ratio and GA, but not HbA 1c , levels were significantly and positively related to poor cognitive function, and these associations were stronger for the GA/HbA 1c ratio than for GA (17) . In addition, one prospective longitudinal study showed a positive, but nonsignificant, association between GA levels and the risk of AD among a US population (18) . These findings are in accord with ours. Therefore, the present findings suggest that the GA/HbA 1c ratio is more strongly associated with the risk of AD than other glycemic measures.
In the present analysis, no clear association of HbA 1c levels with the risk of AD was detected. The findings of previous prospective studies on this issue have been discordant; a study of primary care patients has shown that elevated HbA 1c levels were significantly associated with the risk of incident AD (11), whereas a marginal positive association between HbA 1c levels and the incidence of all-cause dementia or mild cognitive impairment was observed in another study of postmenopausal women with osteoporosis (8) . In contrast, no obvious association between HbA 1c and all-cause dementia was found in two community-based studies of subjects with diabetes (9, 10) . In addition, a randomized control trial of patients with type 2 diabetes failed to demonstrate a preventive effect on cognitive decline by lowering HbA 1c (30) . On the basis of the totality of available data, there seems to be no strong evidence of an association between higher HbA 1c levels and the risk of dementia, including AD.
The mechanisms through which the risk of AD increased with higher GA/HbA 1c ratio are unclear. Our Because serum 1,5-AG levels are decreased in the presence of hyperglycemia, the highest quartile was used as the reference group for 1,5-AG. a Multivariable adjustment was made for age, sex, hypertension, total cholesterol, body mass index category (underweight, normal, and obesity), history of stroke, low education, smoking habits, alcohol intake, and physical activity. b Multivariable adjustment was made for antidiabetic medication and duration of diabetes [no diabetes, newly diagnosed diabetes, and known diabetes (duration of diabetes, ,5, 5-9, and $10 years)] in addition to variables included in model shown in preceding footnote.
subjects with increased GA/HbA 1c ratio levels had higher frequencies of anemia, renal failure, and underweight, which indicate underlying health issues, but the exclusion of subjects with these health conditions did not alter the findings. Possible explanations for the association between the GA/HbA 1c ratio and the risk of AD are as follows. Oxidative stress has been proposed to be involved in the pathogenic processes causing AD (1, 31) . It has also been reported that acute hyperglycemia or postprandial hyperglycemia had a more specific triggering effect on oxidative stress than chronic sustained hyperglycemia (32, 33) . In support of these results, we previously showed that postprandial hyperglycemia, but not fasting hyperglycemia, was significantly associated with an increased risk of AD (3), the formation of neuritic plaques (4), and hippocampal atrophy (5). Meanwhile, HbA 1c represents the average plasma glucose levels, but does not provide an indication of acute elevation of plasma glucose (16, 34, 35) , whereas GA has been found to reflect postprandial hyperglycemia and glucose excursion, in addition to mean plasma glucose levels (14, 36, 37) . In contrast, it has been reported that the GA/HbA 1c ratio is reflective of postprandial glucose concentrations or glucose fluctuations rather than the average plasma glucose levels (14, 37) . Recent clinical studies using CGM or self-monitoring of blood glucose have also revealed that the GA/HbA 1c ratio was a better marker of glucose excursion than GA or HbA 1c alone (16, 37) . Furthermore, a clinical study has reported that HbA 1c levels were positively correlated with a marker of oxidative stress (38) , and GA has also been shown to be significantly associated with increased production of reactive oxygen species in an experimental study (39) . Thus, it is assumed that HbA 1c is likely to be a marker of oxidative stress caused by chronic hyperglycemia, whereas the GA/HbA 1c ratio can be considered a marker of oxidative stress induced by acute elevation of plasma glucose. Considering these findings, higher GA/HbA 1c ratio levels may be strongly associated with the risk of AD through oxidative stress arising from acute hyperglycemia. Notably, the current study demonstrated that a close association between high GA/HbA 1c ratio levels and the risk of AD incidence was observed both in subjects with normal glucose tolerance and those with glucose intolerance. Because it has been shown that a rapid rise in plasma glucose induced oxidative stress not only in subjects with type 2 diabetes but also in normal subjects (33) , acute hyperglycemia might augment the risk of AD even in subjects with normal glucose tolerance. Further Figure 2 . Multivariable-adjusted HRs and 95% CIs of each glycemic measure for the development of AD according to the presence or absence of glucose intolerance. High levels of each glycemic measure were defined as the third and upper quartiles of its values; low levels of each glycemic measure were defined as the first and second quartiles of its values. Multivariable adjustment was made for age, sex, hypertension, total cholesterol, body mass index category (underweight, normal, and obesity), history of stroke, low education, smoking habits, alcohol intake, and physical activity. *HRs for high vs low levels of HbA 1c , GA, and GA/HbA 1c ratio, and for low vs high levels of 1,5-AG. Diamonds indicate point estimates of HRs, and bars indicate 95% CIs. GI, glucose intolerance.
exploration is necessary to validate these hypotheses and clarify other underlying mechanisms.
The current study demonstrated no significant association between 1,5-AG levels and the risk of developing AD. The 1,5-AG level relies on the magnitude of glycosuria rather than plasma glucose levels (13) . In addition, an epidemiological study has shown that 1,5-AG levels were less correlated with postprandial glucose excursion than GA levels (36) . Thus, 1,5-AG might less accurately indicate postprandial hyperglycemia than GA or the GA/HbA 1c ratio.
The strengths of our study include the evaluation of the four glycemic measures, longitudinal population-based design, high participation rate, perfect follow-up of subjects, and a morphological examination of the brains of most AD cases using neuroimaging and autopsy. However, some limitations should be mentioned. First, each glycemic measure was based on a single measurement, as was the case in most other epidemiological studies. This limitation may have caused some degree of misclassification of the levels of glycemic measures, and such misclassification could have weakened the association found in our study, biasing the results toward the null hypothesis. Second, there may have been a selection bias resulting from the exclusion of subjects with missing glycemic measurements (n = 226). Compared with the subjects included in the study, those excluded were more likely to be older and female, and had more frequent antidiabetic medications, hypertension, underweight, and history of stroke. This might have resulted in the underestimation of the study findings. Third, there is a possibility of reverse causation: namely, subjects with underlying dementia might have already changed their lifestyle, including dietary or physical exercise habits. This limitation may have led to alteration in levels of glycemic measures. However, when the analysis was restricted to persons with $2 years of follow-up, there were no material differences in our findings (data not shown). Fourth, information on mild cognitive impairment at the baseline and during follow-up was not available in this study. Fifth, a significant difference in the influence of each glycemic measure on the risk of AD was not detected between the sexes, age groups, and levels of dietary factors in our study. However, these findings were considered inconclusive, because of the relatively small number of AD cases in this study. In addition, we could not address the influence of other dietary factors possibly affecting postprandial glucose levels, such as the glycemic index and glycemic load, on the risk of AD. Additional large-scale investigation would help to elucidate these issues. Lastly, we may have been unable to completely eliminate the influence of residual confounding by unknown risk factors.
In conclusion, the current study showed that elevated GA/HbA 1c ratio levels were more strongly associated with incident AD than HbA 1c , GA, and 1,5-AG levels both in subjects with and those without glucose intolerance in a general population, suggesting that the GA/HbA 1c ratio is a useful biomarker for predicting incident AD. The use of the GA/HbA 1c ratio in clinical practice may help to extract individuals at high risk of AD, which is increasingly recognized as a global health priority. Further epidemiological and basic studies are needed to verify these findings and underlying mechanisms.
